ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was established in the PRC in June 2015. ImmuneOnco is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. ImmuneOnco is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. Currently approved immunotherapies primarily focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. Harnessing both the innate and adaptive immune systems allows us to overcome the limitations of current T-cell-based immunotherapies and address substantial unmet medical needs of cancer patients.
Milestone Payment of $5 Million Received for IMM2510 and IMM27M Collaboration between ImmuneOnco and Instil Bio
2025 WCLC | ImmuneOnco’s Peviplamab (IMM2510) Phase I Clinical Study in Advanced Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) Post-Immune Therapy Selected for Poster Presentation
ImmuneOnco’s Amulirafusp Alfa (IMM0306) for Lymphoma Accepted for Full Publication by the Journal of Hematology & Oncology
Integrated proprietary R&D engine anchored around our deep understanding of tumor immunology, continuously driving the discovery and development of immunotherapies.
Integrated proprietary R&D engine anchored around our deep understanding of tumor immunology, continuously driving the discovery and development of innovative next-generation immunotherapies.
With a rich next-generation immuno-oncology pipeline harnessing both the innate and adaptive immune systems
Harnessing both the innate and adaptive immune systems allows us to overcome the limitations of current T-cell-based immunotherapies and address significant unmet medical needs of cancer patients.
